Covishield produces more antibodies than Covaxin: Study

NEW DELHI: A study conducted by the Coronavirus Vaccine-induced Antibody Titre (COVAT) has suggested that Serum Institute’s Covishield produces more antibodies than Covaxin manufactured by Bharat Biotech. The study was conducted on the health workers who have received both the doses of any one of the vaccines.

The study said that both the vaccines – Covishield and Covaxin have shown good response after two doses. The study reported that amongst 552 participants, 456 and 96 were administered the first dose of Covishield and Covaxin, respectively. 79.3 per cent of them reported sero-positivity after receiving the first dose of vaccine. The health care workers who were administered the dose of either of them were with or without past infection of the novel coronavirus.

The conclusion of the study shows that both the vaccine produced good immune response, however, Covishield recipient developed more antibodies compared to Covaxin. The study will shed further light on the immune response of the two vaccines after the second dose is administered.